share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 18 16:38
Summary by Futu AI
赛生药业於2024年4月17日公布，根據香港《公司收購及合併守則》規則22，公司關聯人Peter Shao Chihwen於2024年4月5日透過首次公開發售後受限股份單位計劃買入48,750股股份，每股價格為$0.0000，交易後持股數量為80,831股，佔公司同類別證券百分之0.0129%。該交易為個人帳戶交易，並於4月17日由執行人員接獲披露。
赛生药业於2024年4月17日公布，根據香港《公司收購及合併守則》規則22，公司關聯人Peter Shao Chihwen於2024年4月5日透過首次公開發售後受限股份單位計劃買入48,750股股份，每股價格為$0.0000，交易後持股數量為80,831股，佔公司同類別證券百分之0.0129%。該交易為個人帳戶交易，並於4月17日由執行人員接獲披露。
Sai Seng Pharmaceuticals announced on 17 April 2024 that under Rule 22 of the Hong Kong Code of Acquisitions and Mergers, Peter Shao Chihwen, an associate of the Company, purchased 48,750 shares at a price of $0.0000 per share on 5 April 2024 through an initial public offering restricted share plan, at a price of $0.0000 per share and a post-transaction holding of 80,0,00 shares. 831 shares representing 0.0129% of the company's class securities. The transaction is a personal account transaction and was disclosed by the executors on April 17.
Sai Seng Pharmaceuticals announced on 17 April 2024 that under Rule 22 of the Hong Kong Code of Acquisitions and Mergers, Peter Shao Chihwen, an associate of the Company, purchased 48,750 shares at a price of $0.0000 per share on 5 April 2024 through an initial public offering restricted share plan, at a price of $0.0000 per share and a post-transaction holding of 80,0,00 shares. 831 shares representing 0.0129% of the company's class securities. The transaction is a personal account transaction and was disclosed by the executors on April 17.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.